Fifth Annual Hepatology Update for Primary Care: A Practical Approach

APRIL 29, 2023

Houston Methodist Research Institute
6670 Bertner Ave.
John F. Bookout Auditorium, 2nd Floor
Houston, TX 77030

Course Co-Directors:
Rashid Khan, MD, FACP, FACG, FAASLD
Kimmerlee Boyd, DO
AGENDA

<table>
<thead>
<tr>
<th>TIME</th>
<th>PRESENTATION</th>
<th>SPEAKER</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:30 AM</td>
<td>Registration and Breakfast</td>
<td></td>
</tr>
<tr>
<td>9:15 AM</td>
<td>Welcome, Introduction, and Conference Overview</td>
<td>Rashid Khan, MD, FACP, FACC, FAASLD</td>
</tr>
<tr>
<td>9:30 AM</td>
<td>Inpatient Liver Consults - Do's and Don'ts</td>
<td>Tamneet Basra, MD</td>
</tr>
<tr>
<td>10:00 AM</td>
<td>The Interventional Radiologist and the Liver</td>
<td>Nassim Akle, MD</td>
</tr>
<tr>
<td>10:30 AM</td>
<td>Hepatitis C and Other Viruses - Update 2023</td>
<td>David W. Victor, III, MD</td>
</tr>
<tr>
<td>11:00 AM</td>
<td>Break and Exhibits</td>
<td></td>
</tr>
<tr>
<td>11:30 AM</td>
<td>Care of the ESLD (End-stage Liver Disease) Patient in the Primary Care Office</td>
<td>Sudha Kodali, MD, MSPH</td>
</tr>
<tr>
<td>12:00 PM</td>
<td>Alcoholic Liver Disease Update and Lessons During/After Covid Era</td>
<td>Victor Ankoma-Sey, MD, FACP, FAASLD</td>
</tr>
<tr>
<td>12:30 PM</td>
<td>Adjourn/Lunch</td>
<td></td>
</tr>
</tbody>
</table>

Click the link of the presentation to view the presentation slides (PDF)*.
Presentation slides are posted as they become available. Some slides may not be posted.
Refresh and click on the presentation link to check for updates.
Are the links not showing? We suggest trying another browser or downloading this pdf and opening it with a pdf viewer.
COURSE DIRECTORS

Rashid Khan, MD, FACP, FACG, FAASLD
Gastroenterology/Transplant Hepatology
Houston Methodist Baytown

Kimmerlee Boyd, DO
Internal Medicine Hospitalist
Houston Methodist Baytown Hospital
Clinical Educator, Internal Medicine and Family Medicine Residents

HOUSTON METHODIST FACULTY

Nassim Akle, MD
Associate Professor of Radiology
Weill Cornell Medical College
Houston Methodist
Interventional and Neuroradiologist
Houston Radiology Associated

Victor Ankoma-Sey, MD, FACP, FAASLD
Director, Liver Transplant Program
Transplant Hepatologist, Sherrie and Alan Conover Center for Liver Disease & Transplantation
Houston Methodist J.C. Walter Jr. Transplant Center
Director, Liver Associates of Texas, PA

Tamneet Basra, MD
Transplant Hepatologist, Sherrie and Alan Conover Center for Liver Disease & Transplantation
Houston Methodist J.C. Walter Jr. Transplant Center

Sudha Kodali, MD, MSPH
Director, Hepatocellular Carcinoma Program
Transplant Hepatologist, Sherrie and Alan Conover Center for Liver Disease & Transplantation
Houston Methodist J.C. Walter Jr. Transplant Center
Associate Professor of Medicine
Houston Methodist
Weill Cornell Medical College

David W. Victor III, MD
Director, Metabolic Liver Disease Program
Director, Clinical Research for Academic Hepatology
Associate Director, Gastroenterology Fellowship Program
Transplant Hepatologist, Sherrie and Alan Conover Center for Liver Disease & Transplantation
Houston Methodist J.C. Walter Jr. Transplant Center
Associate Professor of Medicine
Houston Methodist
Weill Cornell Medical College
PROGRAM OVERVIEW
Liver diseases have become more prevalent and primary care health care professionals face challenges in prompt recognition, diagnosis, and management. The burden of liver ailments is expected to increase further.

The goal of this meeting is to provide an overview of the most common liver diseases seen in the community and to bridge the learning gap between primary care and the latest advances and developments in the field of hepatology. Given the rapid pace of clinical growth in hepatology in the past decade, bridging this gap is particularly significant. A practical approach will be presented so that attendees can integrate into their daily practice.

TARGET AUDIENCE
Primary care physicians, internists, hospitalists, family medicine practitioners, physician assistants, nurse practitioners, nurses, fellows, residents, and medical students will benefit from this course.

EDUCATIONAL OBJECTIVES
At the conclusion of this activity, the participant should be able to:

- Identify the natural history and progression of non-alcoholic fatty liver disease (NAFLD)
- Describe the basics of therapeutics
- Discuss common inpatient liver conditions and management
- Describe the role of the interventional radiologist regarding liver diseases
- Identify recent updates in the treatment of viral hepatitis
- Identify the current approach to alcoholic liver disease, and the impact of the COVID-19 pandemic on this condition
- Discuss the care of the ESLD (End-stage Liver Disease) patient in the primary care office

NURSING OUTCOMES STATEMENT
At the completion of this activity, 80% of the Registered Nurses and Advanced Practice Nurses, will be able to describe at least 1 new learning related to high quality, evidence-based care they can apply to patients and their families, related to new hepatic diseases and treatment modalities for liver disorders, as evidenced by self-reported intent to change practice on the evaluation tool.

EDUCATIONAL METHODS
Didactic Lectures

ACCREDITATION AND CREDIT DESIGNATION STATEMENTS

Physicians
Houston Methodist is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Houston Methodist designates this live activity for a maximum of 2.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
Houston Methodist is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.

Houston Methodist will award 2.67 Nursing Continuing Professional Development contact hours for this activity. Participants must attend the activity in its entirety and complete the corresponding items on the evaluation tool.

HOW TO RECEIVE YOUR CERTIFICATE
An email will be sent from learn@houstonmethodist.org with the necessary link to evaluate the activity. You will be prompted to print/download your certificate in PDF format once you have submitted your evaluation.
DISCLAIMER AND DISCLOSURES
Houston Methodist makes every effort to develop continuing education activities that are scientifically based, accurate, current, and objectively presented. In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education and American Nurse Credentialing Center (ANCC), Houston Methodist has implemented a mechanism requiring everyone in a position to control content of an educational activity (e.g., directors, planning committee members, contributors, peer reviewers, etc.) to disclose all financial relationships with ineligible companies (companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients) and mitigate any relevant financial relationships prior to the activity. Individuals must disclose to participants the existence of financial relationships at the time of the activity and 24 months prior.

Houston Methodist does not view the existence of interests or relationships with ineligible companies as implying bias or decreasing the value of a presentation. It is up to the participants to determine whether the interests or relationships influence the presenter with regard to exposition or conclusions.

In addition, if contributors will be discussing products (drugs/devices) they have been instructed to use generic names and to include various products within and across classes. If at any time during this activity you feel that there has been commercial or promotional bias, please notify the CE coordinator for the activity and note your comments by using the commercial bias comments box in the evaluation form. Please answer the question about balance in the CE activity evaluation candidly.

Some drugs/devices identified during this activity may have United States Food and Drug Administration (FDA) clearance for specific purposes only or for use in restricted research settings. The FDA has stated that it is the responsibility of the individual physician to determine the FDA status of each drug or device that he/she wishes to use in clinical practice and to use the products in compliance with applicable law.

Faculty members are also asked to disclose any unlabeled use or investigational use (not yet approved for any purpose) or pharmaceutical and medical device products and provide adequate scientific and clinical justification for such use. Physicians are urged to fully review all the available data on products or procedures before using them to treat patients.

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Relevant Financial Relationship(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rashid Khan, MD, FACP, FACP, FACG, FAASLD</td>
<td>Planning Committee Member</td>
<td><strong>Speaker:</strong> AbbVie</td>
</tr>
<tr>
<td>David W. Victor III, MD</td>
<td>Speaker</td>
<td><strong>Speaker:</strong> Gilead, Intercept</td>
</tr>
</tbody>
</table>

All the relevant financial relationships listed for these individuals have been mitigated.

All others in control of content for this activity have no relevant financial relationships with ineligible companies to disclose.
EXHIBITORS

We gratefully acknowledge the following companies for participating as exhibitors at this activity:

- AbbVie
- Dynavax
- Gilead
- Intercept
- Ironwood
- Magnolia City Detox
- Perspectum
- Takeda